Aytu BioScience to Report First Quarter Fiscal 2021 Results and Provide Business Update on Thursday, November 12, 2020 – Press Release – Digital…
Posted: November 5, 2020 at 4:58 pm
Live Conference Call and Webcast at 4:30 PM ET
ENGLEWOOD, CO / ACCESSWIRE / November 5, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the fiscal first quarter ended September 30, 2020 on November 12, 2020, at 4:30 p.m. ET. The Company will review accomplishments from the quarter and provide an overview of its business and growth strategy.
Conference Call Information
888-506-0062 (toll-free) Participant Entry Code - 318202973-528-0011 (international) Participant Entry Code - 318202
The webcast will be accessible live and archived at the following link https://www.webcaster4.com/Webcast/Page/2142/38489 and on Aytu BioScience's website, within the Investors section under Events & Presentations, at aytubio.com, for 90 days.
A replay of the call will be available for fourteen days. Access the replay by calling 1-877-481-4010 (toll-free) or 919-882-2331 (international) and using the replay access code 38489.
About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) Cefaclor, a second-generation cephalosporin antibiotic suspension; (ii) Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iii) Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu also distributes a COVID-19 IgG/IgM rapid antibody test. This assay is used in the rapid, qualitative diagnostic assessment of the 2019 Novel Coronavirus. Additionally, Aytu recently licensed worldwide rights to develop the Healight technology platform. Healight is an investigational medical device being studied as a prospective treatment for COVID-19 and other respiratory infections.
Aytu also operates a consumer health subsidiary, Innovus Pharmaceuticals, Inc. ("Innovus"), a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer healthcare products designed to improve men's and women's health and vitality. Innovus commercializes over thirty-five consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the company's proprietary Beyond Human marketing and sales platform.
Aytu's strategy is to continue building its portfolio of revenue-generating Rx and consumer health products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com and visit innovuspharma.com to learn about the company's consumer healthcare products.
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the regulatory and commercial risks associated with introducing the COVID-19 rapid tests, the accuracy of the COVID-19 rapid tests as compared to other COVID-19 tests, market acceptance of the tests, the ability to obtain FDA approval or authorization for the tests, our ability to obtain sufficient tests to meet consumer demand, if any, the manufacturers' ability to scale up manufacturing to meet customer demand, if any, reputation risks if the tests are not as effective as anticipated, and that the current regulatory environment continues to permit the sale of the tests. We also refer you to the risks described in ''Risk Factors'' in Part I, Item 1A of the company's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.
Contact for Media and Investors:
James CarbonaraHayden IR(646) 755-7412james@haydenir.com
SOURCE: Aytu BioScience, Inc.
View source version on accesswire.com: https://www.accesswire.com/614510/Aytu-BioScience-to-Report-First-Quarter-Fiscal-2021-Results-and-Provide-Business-Update-on-Thursday-November-12-2020
Follow this link:
Aytu BioScience to Report First Quarter Fiscal 2021 Results and Provide Business Update on Thursday, November 12, 2020 - Press Release - Digital...
- The Male Hypogonadism Market To Witness An Escalating CAGR Of 3.7% - NeighborWebSJ - January 19th, 2021
- Androgen Replacement Therapy Market to Witness Robust Expansion throughout the Forecast Period 2017-2026 | AbbVie, Inc., Allergan Plc, Bayer AG, Endo... - January 19th, 2021
- Global COVID-19 Diagnostics Market Size Worth USD 11.40 Billion at 7.9% CAGR; Pharmaceutical Giants Such as Abbott and Roche to Pump More Funds for... - January 19th, 2021
- Marius Pharmaceuticals Submits New Drug Application to US FDA for Next-Generation Oral Testosterone Replacement Therapy in Male Patients With... - January 12th, 2021
- Testosterone Replacement Therapy Market (2020 2027) Explosive Factors of Revenue by Key Manufacturer, Share, Future Trends, COVID-19 Market Scenario,... - January 9th, 2021
- The Anabolic Steroids Market to sharpen in the next decade - The Monitor - January 9th, 2021
- Brief Report Treatment of infertility and menopause in a patient with multiple sclerosis affecting the pituitary stalk: a case report - DocWire News - December 24th, 2020
- Male Hypogonadism Therapy Market Detailed Analysis Of Current Industry Figures With Forecasts Growth By 2026 - Cheshire Media - December 6th, 2020
- Male Hypogonadism Market is Expected to Thrive at Impressive CAGR by 2026 & Top Key Players are Astrazeneca Plc., Merck& Co. Inc.,... - December 6th, 2020
- Combination of Radiotherapy and Short-Term Androgen Blockade with Abiraterone Acetate plus Prednisone for M... - UroToday - December 6th, 2020
- Prader-Willi Syndrome Facts: Causes, Diagnosis, Treatments and Prognosis - Gilmore Health News - December 6th, 2020
- Male Hypogonadism HRT Treatment Market 2020-28 booming segments, latest trends and analysis with Merck & Co, Allergan, Endo International,... - December 6th, 2020
- MLB notebook: Red Sox, Rodriguez agree to one-year, $8.3 million deal to avoid arbitration - pressherald.com - December 6th, 2020
- Impact of Covid-19 on Testosterone undecanoate Market is slated to grow rapidly in the forthcoming years with Key Players Bayer AG, Endo... - November 28th, 2020
- Estrogen in men: Symptoms of high and low levels, and more - Medical News Today - November 11th, 2020
- Aytu BioScience to Present at the Jefferies 2020 Virtual London Healthcare Conference Wednesday, November 18 at 1:45pm ET - Stockhouse - November 11th, 2020
- Global Testosterone Replacement Therapy Market 2020 : Industry Analysis by Top Countries Data Definition, Size, Share, Segmentation and Forecast data... - November 11th, 2020
- Male Hypogonadism Therapy Market Forecast to 2027: Top Companies, Trends & Growth Factors and Trend Forecast to 2027 - TechnoWeekly - November 5th, 2020
- The Male Hypogonadism Market To Slither Amidst Covid-19, To Pick Up Pace Post-Covid-19, Reach US$ 3300 Mn - The Think Curiouser - November 5th, 2020
- Global Hypogonadism Drug Market Business Share, Industry Size and Future Investment Opportunities by 2026||ALLERGAN, AstraZeneca, Bayer AG., Eli Lilly... - November 5th, 2020
- Global Hormone Replacement Therapy Market Recent Trends, Development, Growth and Forecast 2020-2027 - Eurowire - November 5th, 2020
- Andropause: Not the same as menopause but needs to be addressed - The Star Online - October 28th, 2020
- Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX (cabozantinib) in Combination with OPDIVO (nivolumab) for the... - October 28th, 2020
- Hormone Replacement Drugs Market Overview With Detailed Analysis, Competitive Landscape, Forecast to 2026|Eli Lilly, Pfizer, AbbVie - Eurowire - October 28th, 2020
- The Anabolic Steroids market to go the reverse transversal way in the next decade - The Think Curiouser - October 25th, 2020
- EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi and Submits Market... - October 25th, 2020
- Male Hypogonadism Therapy Market is Booming Worldwide By Top Key Players: Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,... - October 13th, 2020
- Hormone Replacement Therapy Market Size, Trends, Growth, Key Companies, Forecast by 2026|Eli Lilly, Pfizer, AbbVie - Weekly Wall - October 13th, 2020
- Aytu BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Year-Over-Year - BioSpace - October 10th, 2020
- Aytu BioScience to Report Fourth Quarter and Full Year Fiscal 2020 Results and Provide Business Update on Tuesday, October 6, 2020 - Yahoo Finance - October 10th, 2020
- Sperm Take Up to 3 Years to Recover After Anabolic Steroids - Medscape - October 4th, 2020
- Covid-19 could lower testosterone levels and libido in men - heres what the new study found - Shields Gazette - October 4th, 2020
- Testosterone Replacement Therapy Market 2020 Global Industry Sales, Industry Analysis with Top Countries Data, Share, Trends, Market Demand, Revenue,... - October 4th, 2020
- Treatment of the infertile couple - Contemporary Obgyn - October 4th, 2020
- Testosterone boosters: Uses and effectiveness - Medical News Today - September 22nd, 2020
- Aytu BioScience to Report Fourth Quarter FY 2020 Results and Business Update on Thursday, September 24, 2020 - Yahoo Finance - September 18th, 2020
- H.C. Wainwright Reiterated Lipocine Inc. [LPCN]. What else is Wall St. saying? - The DBT News - September 3rd, 2020
- Hormone Replacement Therapy Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the... - September 3rd, 2020
- Male Hypogonadism Market Estimated to be Driven by Innovation and Industrialization 2017 2026 - The News Brok - August 24th, 2020
- Male Hypogonadism Therapy Industry 2020 Market Size, Share, Price, Trend And Forecast To 2026- Industry Growth Insights - The Scarlet - August 24th, 2020
- Male Hypogonadism Market : Extensive Analysis of Key Segments of the Industry and Emerging Growth Factors with Current Trends and Future Estimations -... - August 24th, 2020
- COVID-19 Impact On Hormone Replacement Therapy Market Size, Status And Forecast 2020-2026 - Galus Australis - August 14th, 2020
- Male Hypogonadism Therapy Market 2020 Size by Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies and Forecast to 2027... - August 13th, 2020
- UB study finds testosterone therapy can lead to remission in men with Type 2 diabetes - UB Now: News and views for UB faculty and staff - University... - August 5th, 2020
- Male Hypogonadism Market 10-Year Market Forecast and Trends Analysis Research Report2017 2026 - The Daily Chronicle - August 4th, 2020
- UB diabetes expert's research shows testosterone therapy can lead to remission in men with Type 2 diabetes - UB News Center - July 31st, 2020
- Hormon replacement therapy Market Growth, Opportunities and Updated Business Strategies|Bayer Pharma - PharmiWeb.com - July 31st, 2020
- What are COVID-19 Impact on Male Hypogonadism Market? & what are Major Drives Which Boost Market Even In Outbreak? - WOLE TV - July 31st, 2020
- Testosterone Replacement Therapy and Its Potential Mental Health Benefits to Men - Press Release - Digital Journal - July 31st, 2020
- Global Testosterone Cypionate Market (Covid-19 Impact) Expected to Witness a Sustainable Growth over 2026 - Market Research Correspondent - July 31st, 2020
- Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration - BioSpace - July 31st, 2020
- What is Male Menopause? Heres everything you need to know about andropause - PINKVILLA - July 26th, 2020
- North America Hormone Replacement Therapy Market: Demand, Share, Size, Industry Trends, Analysis and Forecast during 2020-2025 - Jewish Life News - July 3rd, 2020
- North America Hormone Replacement Therapy Market: Share, Industry Trends, Price, Size, Demand and Forecast to 2020-2025 - 3rd Watch News - July 3rd, 2020
- Testosterone undecanoate Market 2020 | What Will Be the Market Size and the Growth Rate Analysis by 2025? - Cole of Duty - July 1st, 2020
- Advancements in treatments in healthcare is boosting the Human Chorionic Gonadotropin (HCG) Market - Day Web Chronicle - July 1st, 2020
- Global Hormone Replacement Therapy Market 2020 Research by Business Analysis, Growth Strategy and Industry Development to 2025 - Cole of Duty - July 1st, 2020
- No fountain of youth: Just because theres a way to boost testosterone doesnt mean you should, experts warn - The Gardner News - June 22nd, 2020
- Human Chorionic Gonadotropin (hCG) Market Insights on Growth Trends, Top Players, Types, Applications and Regional Analysis - Personal Injury Bureau... - June 22nd, 2020
- Male Hypogonadism Therapy Market Research Growth by Manufacturers, Regions, Type and Application, Forecast Analysis to 2026 - CueReport - June 20th, 2020
- Emerging Opportunity in Transdermal Testosterone Market with Eminent Key Players and Future Outlook to 2024: AbbVie, Teva, Perrigo, Endo... - June 20th, 2020
- No fountain of youth: Just because theres a way to boost testosterone doesnt mean you should, experts warn - Lexington Dispatch - June 20th, 2020
- Testosterone Gel Market: 2020 Industry Trends, Size, Growth Predictions, Segmentation, Business Statistics, Top Key Players and 2026 Forecast Research... - June 18th, 2020
- Anabolic Steroids Market to Witness Heightened Revenue Growth in the Next Decade - Owned - June 18th, 2020
- Male Hypogonadism Therapy Market Business Analysis 2020 by Leading Industrial Source, Statistics, Gross Margin, Upstream Analysis, Downstream Analysis... - June 14th, 2020
- QOL and body composition benefits seen with novel oral T treatment - Urology Times - June 14th, 2020
- Novel oral testosterone therapy shows liver health benefits - Urology Times - June 14th, 2020
- Rising infertility related issues are boosting the growth of the Human Chorionic Gonadotropin (HCG) Market - Day Web Chronicle - June 5th, 2020
- Male Hypogonadism Therapy Market Development, Market Trends, Key Driven Factors, Segmentation And Forecast To 2020-2026 - Weekly Wall - June 4th, 2020
- Jacobs School appoints new chair of Obstetrics and Gynecology - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter - June 4th, 2020
- Demanded Report on Male Hypogonadism Market Analysis Forecast with Leading Key Players: AbbVie Inc., Allergan plc, Astrazeneca plc, Bayer AG., Eli... - May 30th, 2020
- COVID-19: Responding to the business impacts of Global Male Hypogonadism Market : Current Trends and Future Estimations to Elucidate Imminent... - May 30th, 2020
- Transdermal Testosterone Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026| - Jewish Life News - May 30th, 2020
- Scientists Discover New Sexual Hormone that Could Offer Better Fertility Treatments - Science Times - May 30th, 2020
- COVID-19 Impact on Global Steroids Market 2020: Industry Trends, Size, Share, Applications, SWOT Analysis by Top Key Players and Forecast Report to... - May 30th, 2020
- Marius Pharmaceuticals Announces Issuance of Two Key Patents Protecting its Proprietary Oral Testosterone Therapy - Yahoo Finance - May 23rd, 2020
- The Economic Impact of Coronavirus on Male Hypogonadism Market Analysis and Value Forecast Snapshot by End-use Industry 2019-2021 - 3rd Watch News - May 23rd, 2020
- Men With Hypogonadism Leading to Low Testosterone Levels are More Likely to Die From the Coronavirus, Study Fi - Science Times - May 14th, 2020
- Male Hypogonadism Therapy Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty - May 14th, 2020
- Male Hypogonadism Market to Witness over CAGR Growth in Revenue During the COVID-19 Pandemic - Germany English News - May 14th, 2020